A New Type of Targeted Therapy for Leukemia
The FDA has approved the first of a new type of molecularly targeted therapy for use in treating certain...
Progress Against Cancer
The FDA has approved the first of a new type of molecularly targeted therapy for use in treating certain...
The new therapeutic was approved by the FDA for treating patients whose leukemia tests positive for a mutation in...
The FDA decision means tisagenlecleucel (Kymriah) is now approved for certain types of non-Hodgkin lymphoma and acute lymphoblastic leukemia....
Researchers identified mutations in leukemias that may make them amenable to FDA-approved ALK inhibitors Using genomic sequencing, researchers identified...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 44,000 members worldwide drive progress against cancer.
Donate Today